相关实验视频

Updated: Jan 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

利图西马布与循环胺诱导疗法用于患有ANCA相关血管炎的患者

Wenyi Wu¹, Juan Wang¹, Sheng Chen²

¹Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

BMC rheumatology

|November 29, 2025

概括

利图西马布 (RTX) 在ANCA相关血管炎 (AAV) 缓解方面显示出与环胺 (CYC) 相似的有效性. 对于PR3-ANCA阳性患者来说,RTX提供了好处,但增加了尿路感染的风险.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

与ANCA相关的血管炎 (AAV) 是一组需要有效的免疫抑制治疗的自身免疫性疾病.
利图西马布 (RTX) 和环胺 (CYC) 是常用的诱导治疗AAV.
在AAV中,RTX与CYC有效性和安全性的比较数据对于治疗决策至关重要.

研究的目的:

为了比较Rituximab (RTX) 与Cyclophosphamide (CYC) 的疗效和安全性,用于诱导ANCA相关血管炎 (AAV) 患者的缓解.
确定可能从RTX或CYC治疗中获益更多的患者子组.
评估与RTX和CYC诱导疗法相关的感染风险.

主要方法:

从2017年1月到2023年12月,对293名接受RTX或CYC治疗的AAV患者进行了回顾性分析.
用完全缓解率 (CR) 来衡量治疗后6个月的有效性.
通过在6个月内发生感染来评估安全性;用于比较分析的治疗权重的逆概率 (IPTW).

主要成果:

对治疗权重的反向概率 (IPTW) 权衡分析显示,与CYC (31.3%) 相比,RTX (41.4%) 的完全缓解率 (CR) 较高.
接受RTX的人患尿路感染的几率显著增加 (OR 10.20).
亚组分析表明,在PR3-ANCA阳性患者中,RTX具有明显的益处.

结论:

利图西马布 (RTX) 在诱导ANCA相关血管炎 (AAV) 缓解方面与环胺 (CYC) 一样有效.
在PR3-ANCA阳性患者中,RTX表现出特别高的疗效.
使用RTX与尿路感染的风险增加有关.

关键词:

与ANCA相关的血管炎环酸胺的使用方法有效性有效性.诱导疗法是一种诱导疗法.感染感染感染里图西马布 (Rituximab) 是一种药物.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...